Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging

References

1. 1.↵
   1. Fox RJ

   . Picturing multiple sclerosis: conventional and diffusion tensor imaging. Semin Neurol 2008;28:453–66

   CrossRefPubMed
2. 2.↵
   1. Basser PJ,
   2. Pierpaoli C

   . Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson 1996;111:209–19

   CrossRefWeb of Science
3. 3.↵
   1. Pierpaoli C,
   2. Basser PJ

   . Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996;36:893–906

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Kim JH,
   2. Budde MD,
   3. Liang HF,
   4. et al

   . Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis 2006;21:626–32

   CrossRefPubMedWeb of Science
5. 5.↵
   1. DeBoy CA,
   2. Zhang J,
   3. Dike S,
   4. et al

   . High-resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain 2007;130:2199–210

   Abstract/FREE Full Text
6. 6.↵
   1. Concha L,
   2. Gross DW,
   3. Wheatley BM,
   4. et al

   . Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosotomy in epilepsy patients. Neuroimage 2006;32:1090–99

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Schmierer K,
   2. Wheeler-Kingshott CA,
   3. Boulby PA,
   4. et al

   . Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage 2007;35:467–77. Epub 2006 Dec 16

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Song SK,
   2. Sun SW,
   3. Ju WK,
   4. et al

   . Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage 2003;20:1714–22

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Song SK,
   2. Sun SW,
   3. Ramsbottom MJ,
   4. et al

   . Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage 2002;17:1429–36

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Fox RJ,
    2. McColl RW,
    3. Lee JC,
    4. et al

    . A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury. Arch Neurol 2008;65:1179–84

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Lowe MJ,
    2. Horenstein C,
    3. Hirsch JG,
    4. et al

    . Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis. Neuroimage 2006;32:1127–33

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Naismith RT,
    2. Xu J,
    3. Tutlam NT,
    4. et al

    . Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009;72:589–94

    Abstract/FREE Full Text
13. 13.↵
    1. Cox RW

    . AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162–73

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW,
    4. et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208–19

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Prineas JW,
    2. Barnard RO,
    3. Kwon EE,
    4. et al

    . Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137–51

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Raine CS,
    2. Wu E

    . Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993;52:199–204

    PubMedWeb of Science
17. 17.↵
    1. Prineas JW,
    2. Kwon EE,
    3. Cho ES,
    4. et al

    . Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann N Y Acad Sci 1984;436:11–32

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Song SK,
    2. Yoshino J,
    3. Le TQ,
    4. et al

    . Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005;26:132–40

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Wang S,
    2. Wu EX,
    3. Tam CN,
    4. et al

    . Characterization of white matter injury in a hypoxic-ischemic neonatal rat model by diffusion tensor MRI. Stroke 2008;39:2348–53

    Abstract/FREE Full Text
20. 20.↵
    1. Mac Donald CL,
    2. Dikranian K,
    3. Song SK,
    4. et al

    . Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol 2007;205:116–31

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Kumar R,
    2. Gupta RK,
    3. Elderkin-Thompson V,
    4. et al

    . Voxel-based diffusion tensor magnetic resonance imaging evaluation of low-grade hepatic encephalopathy. J Magn Reson Imaging 2008;27:1061–68

    CrossRefPubMed
22. 22.↵
    1. Kale RA,
    2. Gupta RK,
    3. Saraswat VA,
    4. et al

    . Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 2006;43:698–706

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Toh CH,
    2. Castillo M,
    3. Wong AM,
    4. et al

    . Differentiation between classic and atypical meningiomas with use of diffusion tensor imaging. AJNR Am J Neuroradiol 2008;29:1630–35

    Abstract/FREE Full Text
24. 24.↵
    1. Sundgren PC,
    2. Fan X,
    3. Weybright P,
    4. et al

    . Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 2006;24:1131–42

    CrossRefPubMedWeb of Science
25. 25.↵
    1. van Walderveen MA,
    2. Kamphorst W,
    3. Scheltens P,
    4. et al

    . Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282–88

    Abstract/FREE Full Text
26. 26.↵
    1. Bitsch A,
    2. Kuhlmann T,
    3. Stadelmann C,
    4. et al

    . A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001;49:793–96

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Fisher E,
    2. Chang A,
    3. Fox RJ,
    4. et al

    . Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann Neurol 2007;62:219–28

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Miller DH,
    2. Soon D,
    3. Fernando KT,
    4. et al

    . MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390–401

    Abstract/FREE Full Text
29. 29.↵
    1. Oreja-Guevara C,
    2. Rovaris M,
    3. Iannucci G,
    4. et al

    . Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol 2005;62:578–84

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Agosta F,
    2. Absinta M,
    3. Sormani MP,
    4. et al

    . In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 2007;130:2211–19

    Abstract/FREE Full Text
31. 31.↵
    1. Jones DK

    . The effect of gradient sampling schemes on measures derived from diffusion tensor MRI: a Monte Carlo study. Magn Reson Med 2004;51:807–15

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Miller DH,
    2. Khan OA,
    3. Sheremata WA,
    4. et al

    . A controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2003;348:15–23

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Rudick RA,
    2. Stuart WH,
    3. Calabresi PA,
    4. et al

    . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911–23

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Polman C,
    2. O'Connor P,
    3. Havrdova E,
    4. et al

    . Clinical results from AFFIRM: a randomized double-blind, placebo-controlled, multicentrer trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS). Neurology 2005;64(suppl 1):A146
35. 35.↵
    1. Dalton CM,
    2. Miszkiel KA,
    3. Barker GJ,
    4. et al

    . Effect of natalizumab on conversion of gadolinium-enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407–13

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Brocke S,
    2. Piercy C,
    3. Steinman L,
    4. et al

    . Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999;96:6896–901

    Abstract/FREE Full Text
37. 37.↵
    1. Yednock TA,
    2. Cannon C,
    3. Fritz LC,
    4. et al

    . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63–66

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Trapp BD,
    2. Nave KA

    . Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247–69

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Imitola J,
    2. Chitnis T,
    3. Khoury SJ

    . Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 2006;63:25–33

    CrossRefPubMedWeb of Science